Eton Pharmaceuticals (ETON) EBIT (2018 - 2025)

Eton Pharmaceuticals (ETON) has 8 years of EBIT data on file, last reported at $2.5 million in Q4 2025.

• For the quarter ending Q4 2025, EBIT rose 291.73% year-over-year to $2.5 million; the trailing twelve-month figure through Dec 2025 stood at -$844000.0 (up 67.5% YoY), and the FY2025 full-year result was -$844000.0, up 67.5% from the prior year.
• EBIT grew to $2.5 million in Q4 2025, from -$1.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $5.4 million in Q1 2021 to a low of -$5.8 million in Q3 2021.
• A 5-year average of -$719400.0 and a median of -$1.1 million in 2022 frame the typical range for EBIT.
• Across the five-year window, EBIT surged 389.78% in 2023 and tumbled 367.78% in 2025, its largest moves.
• Tracing ETON's EBIT over 5 years: stood at $1.3 million in 2021, then declined by 19.18% to $1.1 million in 2022, then sank by 287.66% to -$2.0 million in 2023, then soared by 131.56% to $629000.0 in 2024, then surged by 291.73% to $2.5 million in 2025.
• Business Quant data shows ETON's EBIT at $2.5 million in Q4 2025, -$1.4 million in Q3 2025, and -$1.5 million in Q2 2025.